BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34072659)

  • 1. Study of the Genetic Variants in
    Solano AR; Mele PG; Jalil FS; Liria NC; Podesta EJ; Gutiérrez LG
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 4. NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of
    Zanti M; Loizidou MA; Michailidou K; Pirpa P; Machattou C; Marcou Y; Kyriakou F; Kakouri E; Tanteles GA; Spanou E; Spyrou GM; Kyriacou K; Hadjisavvas A
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33120919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
    Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
    ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
    Bu R; Siraj AK; Al-Rasheed M; Iqbal K; Azam S; Qadri Z; Haqawi W; Tulbah A; Al-Dayel F; Almalik O; Al-Kuraya KS
    Sci Rep; 2023 Nov; 13(1):20924. PubMed ID: 38017116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel pathogenic variant in
    Laraqui A; Cavaillé M; Uhrhammer N; ElBiad O; Bidet Y; El Rhaffouli H; El Anaz H; Rahali DM; Kouach J; Guelzim K; Badaoui B; AlBouzidi A; Oukabli M; Tanz R; Sbitti Y; Ichou M; Ennibi K; Sekhsokh Y; Bignon YJ
    J Genomics; 2021; 9():43-54. PubMed ID: 34646395
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Incorvaia L; Fanale D; Bono M; Calò V; Fiorino A; Brando C; Corsini LR; Cutaia S; Cancelliere D; Pivetti A; Filorizzo C; La Mantia M; Barraco N; Cusenza S; Badalamenti G; Russo A; Bazan V
    Ther Adv Med Oncol; 2020; 12():1758835920975326. PubMed ID: 33403015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Germline Mutations in a Cohort of 250 Relatives of Mutation Carriers in Multigene Panel: Impact of Pathogenic Variants in Other Genes beyond
    Di Rado S; Giansante R; Cicirelli M; Pilenzi L; Dell'Elice A; Anaclerio F; Rimoldi M; Grassadonia A; Grossi S; Canale N; Ballerini P; Stuppia L; Antonucci I
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline
    Nerone M; Rossi L; Condorelli R; Ratti V; Conforti F; Palazzo A; Graffeo R
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
    Chavarri-Guerra Y; Villarreal-Garza C; Ferrigno AS; Mohar A; Aguilar D; Alvarez-Gomez RM; Gallardo-Alvarado L; Del Toro-Valero A; Quintero-Beulo G; Gutierrez-Delgado F; Rodriguez-Olivares JL; Ochoa-Chavez MF; Gutierrez-Seymour G; Castillo D; Herzog J; Weitzel JN
    Salud Publica Mex; 2022 Feb; 64(1):41-48. PubMed ID: 35438911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk.
    Lang GT; Shi JX; Huang L; Cao AY; Zhang CH; Song CG; Zhuang ZG; Hu X; Huang W; Shao ZM
    Ann Transl Med; 2020 Nov; 8(21):1417. PubMed ID: 33313162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in
    Incorvaia L; Fanale D; Badalamenti G; Bono M; Calò V; Cancelliere D; Castiglia M; Fiorino A; Pivetti A; Barraco N; Cutaia S; Russo A; Bazan V
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.